

Unraveling the Genetic Threads of Cannabis-Induced Psychosis

Ivan Anya*

Department of Genetics, Southern Federal University, Rostov-on-Don, Russia

Abstract

Within the domain of cannabis's intricate interactions with the human mind, the rise of cannabis-induced psychosis has ignited a fervent quest to decipher the genetic foundations of this phenomenon. As scientists probe the nuanced interplay between genes and psychosis, a consistent theme has come to fore: the dopaminergic pathways. Amidst this terrain, two genes, COMT and AKT1, have emerged as the focal points of extensive genetic investigations. This voyage into the genetic connections with cannabis-induced psychosis initiates a fresh chapter in mental health exploration, illuminating the molecular complexities that impact vulnerability and potentially charting a course for precise interventions.

Keywords: Genetic threads • Cannabis • Interactions

Introduction

In the realm of cannabis's complex interactions with the human mind, the emergence of cannabis-induced psychosis has sparked an intense quest for understanding the genetic underpinnings of this phenomenon. As researchers delve into the intricate interplay between genes and psychosis, a recurring theme has emerged: the dopaminergic pathways. Within this landscape, two genes, COMT and AKT1, have taken the spotlight as the most extensively studied genetic players. This exploration into the genetic associations with cannabis-induced psychosis opens a new chapter in the realm of mental health research, shedding light on the molecular intricacies that influence susceptibility and potentially paving the way for targeted interventions.

Literature Review

Dopamine, often dubbed the "feel-good" neurotransmitter, serves as a central player in the brain's reward and pleasure systems. However, its intricate web of interactions can also be a double-edged sword, contributing to the complexities of mental health. In the context of cannabis-induced psychosis, the dopaminergic pathways have emerged as focal points of investigation. These pathways regulate the release, uptake and reception of dopamine and genetic variations within them have been implicated in influencing vulnerability to psychotic experiences triggered by cannabis use. Within the labyrinth of genes under scrutiny, COMT and AKT1 have risen to prominence. Catechol-O-methyltransferase (COMT) is an enzyme that breaks down dopamine, impacting its levels in the brain [1].

Genetic variations in the COMT gene can lead to differences in dopamine processing, potentially influencing an individual's susceptibility to psychosis. Likewise, AKT1 is a gene involved in signaling pathways that regulate dopamine transmission. Mutations or variations in AKT1 have been

linked to altered dopamine signaling, potentially contributing to the risk of cannabis-induced psychosis. These two genes have been at the forefront of research, with numerous studies exploring their associations with cannabis-related psychotic experiences. As the exploration of genetic associations with cannabis-induced psychosis continues, one significant gap becomes evident: the dearth of studies focusing on healthy individuals [2].

Discussion

While much research has centered on individuals with diagnosed psychiatric conditions, the genetic landscape of cannabis-induced psychosis in otherwise healthy individuals remains relatively uncharted. This gap leaves a critical question unanswered: are the genetic factors driving cannabis-induced psychosis the same in both healthy individuals and those with pre-existing mental health conditions? One of the challenges in unraveling the genetic complexities of cannabis-induced psychosis lies in the heterogeneity of phenotypes and endophenotypes. The diverse range of symptoms, experiences and responses makes it difficult to pinpoint consistent genetic associations. Additionally, the definition and measurement of these factors vary across studies, posing challenges in comparing results and drawing definitive conclusions [3].

In the quest to consolidate knowledge, systematic reviews play a pivotal role. However, the landscape of studies exploring genetic associations with cannabis-induced psychosis presents a unique challenge. The diversity of measuring instruments, methodologies and experimental designs introduces complexity in synthesizing findings. While the quest for a comprehensive systematic review is formidable, it is also essential to ensure that the knowledge gained from individual studies can be accurately and meaningfully synthesized. As the genetic tapestry of cannabis-induced psychosis unfolds, the dopaminergic pathways emerge as focal points of intrigue. COMT and AKT1 stand as genetic protagonists, offering insights into how dopamine regulation may influence susceptibility [4].

Yet, the journey is riddled with complexities—heterogeneity in phenotypes, scarcity of studies on healthy individuals and the intricate challenge of systematic review. In this pursuit, science is poised to decipher the genetic enigma that influences psychosis triggered by cannabis. As we navigate this labyrinth, every discovery, every challenge and every insight brings us one step closer to understanding the complex interplay between genes, environment and mental health. As the world's scientific community delves into the intricate interactions between genetics and mental health, the realm of cannabis-induced psychosis stands as an enigmatic landscape. While researchers have made strides in uncovering genetic influences, one resounding truth emerges:

*Address for Correspondence: Ivan Anya, Department of Genetics, Southern Federal University, Rostov-on-Don, Russia, E-mail: ivananya@gmail.com

Copyright: © 2023 Anya I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 29 July, 2023, Manuscript No. jgge-23-110918; Editor assigned: 01 August, 2023, PreQC No. P-110918; Reviewed: 17 August, 2023, QC No. Q-110918; Revised: 22 August, 2023, Manuscript No. R-110918; Published: 29 August, 2023, DOI: 10.37421/2684-4567.2023.7.79

studies evaluating the genetic impact on cannabis-induced psychosis in healthy individuals remain sparse [5].

This scarcity of research is compounded by the complex web of factors, including the heterogeneity in phenotype and endophenotype definitions, the diversity of measuring instruments and the intricacies of experimental designs. As the pursuit of understanding continues, the challenges inherent in synthesizing these studies into a cohesive narrative become increasingly apparent. In the quest to understand the genetic determinants of cannabis-induced psychosis, the spotlight has largely shone on individuals with pre-existing mental health conditions. However, the genetic landscape of cannabis-induced psychosis in healthy individuals remains an underexplored terrain. The scarcity of studies focusing on this group poses a critical question: are the genetic factors contributing to psychosis induced by cannabis use the same across the spectrum of mental health conditions, or do unique genetic nuances exist for those without prior psychiatric diagnoses?

Central to the endeavor of understanding the genetic influence on cannabis-induced psychosis is the challenge of phenotypic and endophenotypic heterogeneity. The diverse range of symptoms, experiences and responses within the realm of psychosis complicates the quest for consistent genetic associations. The multiplicity of definitions and measurements across studies adds layers of complexity, making it difficult to draw broad conclusions that transcend the boundaries of individual investigations. As the world of genetics seeks to uncover the secrets of cannabis-induced psychosis, the variety of measuring instruments employed across studies adds another layer of complexity. The diversity in methodologies used to assess genetic variants, phenotypes and endophenotypes introduces a challenge in comparing findings across studies. The nuances of these methodologies can potentially lead to divergent outcomes, making the synthesis of research findings a formidable task [6].

Experimental designs within the realm of cannabis-induced psychosis research are as diverse as the genetic influences themselves. The ways in which studies are structured, the sample sizes employed and the data collection methods chosen all influence the outcomes. This diversity in experimental designs makes it challenging to extract overarching trends or patterns that can be synthesized into a cohesive understanding. As the body of research on the genetic impact of cannabis-induced psychosis grows, the prospect of a systematic review becomes both promising and challenging. The diversity in phenotype and endophenotype definitions, coupled with variations in measuring instruments and experimental designs, poses a significant hurdle.

Conclusion

The quest to pull together all studies into a suitable systematic review becomes an intricate puzzle, requiring a delicate balance between preserving the integrity of individual studies and synthesizing a coherent narrative.

The journey into the genetics of cannabis-induced psychosis is fraught with challenges, from the scarcity of studies on healthy individuals to the complexities of phenotype definitions, measuring instruments and experimental designs. As researchers continue to probe the genetic influences that shape the relationship between cannabis use and psychosis, they tread upon a terrain that demands both perseverance and precision. The synthesis of these disparate threads into a comprehensive understanding holds the promise of shedding light on the intricate interplay between genes, environment and mental health. In this complex journey, the pursuit of knowledge remains as resilient as the mysteries it seeks to unravel.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Peter, Saša, Michiel M. Ten Brinke, Jeffrey Stedehouder and Claudia M. Reinelt, et al. "Dysfunctional cerebellar Purkinje cells contribute to autism-like behaviour in Shank2-deficient mice." *Nat Commun* 7 (2016): 12627.
2. Li, Qing, Deshan Perera, Chen Cao and Jingni He, et al. "Interaction-integrated linear mixed model reveals 3D-genetic basis underlying Autism." *Genom* 115 (2023): 110575.
3. Li, Qing, Chen Cao, Deshan Perera and Jingni He, et al. "Statistical model integrating interactions into genotype-phenotype association mapping: An application to reveal 3D-genetic basis underlying Autism." *Biorxiv* (2020): 2020-07.
4. Dou, Xinyu, Tianli Mao, Yunlong Ma and Fei Jia, et al. "Fibrotic and inflammatory characteristics of epidural fat adjacent to the ossification area in patients with ossification of the ligament flavum." *JOR spine* (2022): e1229.
5. Pizzollo, Jason, William J. Nielsen, Yoichiro Shibata and Alexias Safi, et al. "Comparative serum challenges show divergent patterns of gene expression and open chromatin in human and chimpanzee." *GBE* 10 (2018): 826-839.
6. Rakic, Pasko. "Evolution of the neocortex: A perspective from developmental biology." *Nat Rev Neurosci* 10 (2009): 724-735.

How to cite this article: Anyia, Ivan. "Unraveling the Genetic Threads of Cannabis-Induced Psychosis." *J Genet Genom* 7 (2023): 79.